Cargando…

Hybrid (18)F-Fluoroethyltyrosine PET and MRI with Perfusion to Distinguish Disease Progression from Treatment-Related Change in Malignant Brain Tumors: The Quest to Beat the Toughest Cases

Conventional MRI has important limitations when assessing for progression of disease (POD) versus treatment-related changes (TRC) in patients with malignant brain tumors. We describe the observed impact and pitfalls of implementing (18)F-fluoroethyltyrosine ((18)F-FET) perfusion PET/MRI into routine...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Nathaniel J., Deaton, Tristan K., Territo, Wendy, Graner, Brian, Gauger, Andrew, Snyder, Scott E., Schulte, Michael L., Green, Mark A., Hutchins, Gary D., Veronesi, Michael C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315704/
https://www.ncbi.nlm.nih.gov/pubmed/37116915
http://dx.doi.org/10.2967/jnumed.122.265149
_version_ 1785067553980153856
author Smith, Nathaniel J.
Deaton, Tristan K.
Territo, Wendy
Graner, Brian
Gauger, Andrew
Snyder, Scott E.
Schulte, Michael L.
Green, Mark A.
Hutchins, Gary D.
Veronesi, Michael C.
author_facet Smith, Nathaniel J.
Deaton, Tristan K.
Territo, Wendy
Graner, Brian
Gauger, Andrew
Snyder, Scott E.
Schulte, Michael L.
Green, Mark A.
Hutchins, Gary D.
Veronesi, Michael C.
author_sort Smith, Nathaniel J.
collection PubMed
description Conventional MRI has important limitations when assessing for progression of disease (POD) versus treatment-related changes (TRC) in patients with malignant brain tumors. We describe the observed impact and pitfalls of implementing (18)F-fluoroethyltyrosine ((18)F-FET) perfusion PET/MRI into routine clinical practice. Methods: Through expanded-access investigational new drug use of (18)F-FET, hybrid (18)F-FET perfusion PET/MRI was performed during clinical management of 80 patients with World Health Organization central nervous system grade 3 or 4 gliomas or brain metastases of 6 tissue origins for which the prior brain MRI results were ambiguous. The diagnostic performance with (18)F-FET PET/MRI was dually evaluated within routine clinical service and for retrospective parametric evaluation. Various (18)F-FET perfusion PET/MRI parameters were assessed, and patients were monitored for at least 6 mo to confirm the diagnosis using pathology, imaging, and clinical progress. Results: Hybrid (18)F-FET perfusion PET/MRI had high overall accuracy (86%), sensitivity (86%), and specificity (87%) for difficult diagnostic cases for which conventional MRI accuracy was poor (66%). (18)F-FET tumor-to-brain ratio static metrics were highly reliable for distinguishing POD from TRC (area under the curve, 0.90). Dynamic tumor-to-brain intercept was more accurate (85%) than SUV slope (73%) or time to peak (73%). Concordant PET/MRI findings were 89% accurate. When PET and MRI conflicted, (18)F-FET PET was correct in 12 of 15 cases (80%), whereas MRI was correct in 3 of 15 cases (20%). Clinical management changed after 88% (36/41) of POD diagnoses, whereas management was maintained after 87% (34/39) of TRC diagnoses. Conclusion: Hybrid (18)F-FET PET/MRI positively impacted the routine clinical care of challenging malignant brain tumor cases at a U.S. institution. The results add to a growing body of literature that (18)F-FET PET complements MRI, even rescuing MRI when it fails.
format Online
Article
Text
id pubmed-10315704
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Society of Nuclear Medicine
record_format MEDLINE/PubMed
spelling pubmed-103157042023-07-04 Hybrid (18)F-Fluoroethyltyrosine PET and MRI with Perfusion to Distinguish Disease Progression from Treatment-Related Change in Malignant Brain Tumors: The Quest to Beat the Toughest Cases Smith, Nathaniel J. Deaton, Tristan K. Territo, Wendy Graner, Brian Gauger, Andrew Snyder, Scott E. Schulte, Michael L. Green, Mark A. Hutchins, Gary D. Veronesi, Michael C. J Nucl Med Clinical Investigation Conventional MRI has important limitations when assessing for progression of disease (POD) versus treatment-related changes (TRC) in patients with malignant brain tumors. We describe the observed impact and pitfalls of implementing (18)F-fluoroethyltyrosine ((18)F-FET) perfusion PET/MRI into routine clinical practice. Methods: Through expanded-access investigational new drug use of (18)F-FET, hybrid (18)F-FET perfusion PET/MRI was performed during clinical management of 80 patients with World Health Organization central nervous system grade 3 or 4 gliomas or brain metastases of 6 tissue origins for which the prior brain MRI results were ambiguous. The diagnostic performance with (18)F-FET PET/MRI was dually evaluated within routine clinical service and for retrospective parametric evaluation. Various (18)F-FET perfusion PET/MRI parameters were assessed, and patients were monitored for at least 6 mo to confirm the diagnosis using pathology, imaging, and clinical progress. Results: Hybrid (18)F-FET perfusion PET/MRI had high overall accuracy (86%), sensitivity (86%), and specificity (87%) for difficult diagnostic cases for which conventional MRI accuracy was poor (66%). (18)F-FET tumor-to-brain ratio static metrics were highly reliable for distinguishing POD from TRC (area under the curve, 0.90). Dynamic tumor-to-brain intercept was more accurate (85%) than SUV slope (73%) or time to peak (73%). Concordant PET/MRI findings were 89% accurate. When PET and MRI conflicted, (18)F-FET PET was correct in 12 of 15 cases (80%), whereas MRI was correct in 3 of 15 cases (20%). Clinical management changed after 88% (36/41) of POD diagnoses, whereas management was maintained after 87% (34/39) of TRC diagnoses. Conclusion: Hybrid (18)F-FET PET/MRI positively impacted the routine clinical care of challenging malignant brain tumor cases at a U.S. institution. The results add to a growing body of literature that (18)F-FET PET complements MRI, even rescuing MRI when it fails. Society of Nuclear Medicine 2023-07 /pmc/articles/PMC10315704/ /pubmed/37116915 http://dx.doi.org/10.2967/jnumed.122.265149 Text en © 2023 by the Society of Nuclear Medicine and Molecular Imaging. https://creativecommons.org/licenses/by/4.0/Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: http://jnm.snmjournals.org/site/misc/permission.xhtml.
spellingShingle Clinical Investigation
Smith, Nathaniel J.
Deaton, Tristan K.
Territo, Wendy
Graner, Brian
Gauger, Andrew
Snyder, Scott E.
Schulte, Michael L.
Green, Mark A.
Hutchins, Gary D.
Veronesi, Michael C.
Hybrid (18)F-Fluoroethyltyrosine PET and MRI with Perfusion to Distinguish Disease Progression from Treatment-Related Change in Malignant Brain Tumors: The Quest to Beat the Toughest Cases
title Hybrid (18)F-Fluoroethyltyrosine PET and MRI with Perfusion to Distinguish Disease Progression from Treatment-Related Change in Malignant Brain Tumors: The Quest to Beat the Toughest Cases
title_full Hybrid (18)F-Fluoroethyltyrosine PET and MRI with Perfusion to Distinguish Disease Progression from Treatment-Related Change in Malignant Brain Tumors: The Quest to Beat the Toughest Cases
title_fullStr Hybrid (18)F-Fluoroethyltyrosine PET and MRI with Perfusion to Distinguish Disease Progression from Treatment-Related Change in Malignant Brain Tumors: The Quest to Beat the Toughest Cases
title_full_unstemmed Hybrid (18)F-Fluoroethyltyrosine PET and MRI with Perfusion to Distinguish Disease Progression from Treatment-Related Change in Malignant Brain Tumors: The Quest to Beat the Toughest Cases
title_short Hybrid (18)F-Fluoroethyltyrosine PET and MRI with Perfusion to Distinguish Disease Progression from Treatment-Related Change in Malignant Brain Tumors: The Quest to Beat the Toughest Cases
title_sort hybrid (18)f-fluoroethyltyrosine pet and mri with perfusion to distinguish disease progression from treatment-related change in malignant brain tumors: the quest to beat the toughest cases
topic Clinical Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315704/
https://www.ncbi.nlm.nih.gov/pubmed/37116915
http://dx.doi.org/10.2967/jnumed.122.265149
work_keys_str_mv AT smithnathanielj hybrid18ffluoroethyltyrosinepetandmriwithperfusiontodistinguishdiseaseprogressionfromtreatmentrelatedchangeinmalignantbraintumorsthequesttobeatthetoughestcases
AT deatontristank hybrid18ffluoroethyltyrosinepetandmriwithperfusiontodistinguishdiseaseprogressionfromtreatmentrelatedchangeinmalignantbraintumorsthequesttobeatthetoughestcases
AT territowendy hybrid18ffluoroethyltyrosinepetandmriwithperfusiontodistinguishdiseaseprogressionfromtreatmentrelatedchangeinmalignantbraintumorsthequesttobeatthetoughestcases
AT granerbrian hybrid18ffluoroethyltyrosinepetandmriwithperfusiontodistinguishdiseaseprogressionfromtreatmentrelatedchangeinmalignantbraintumorsthequesttobeatthetoughestcases
AT gaugerandrew hybrid18ffluoroethyltyrosinepetandmriwithperfusiontodistinguishdiseaseprogressionfromtreatmentrelatedchangeinmalignantbraintumorsthequesttobeatthetoughestcases
AT snyderscotte hybrid18ffluoroethyltyrosinepetandmriwithperfusiontodistinguishdiseaseprogressionfromtreatmentrelatedchangeinmalignantbraintumorsthequesttobeatthetoughestcases
AT schultemichaell hybrid18ffluoroethyltyrosinepetandmriwithperfusiontodistinguishdiseaseprogressionfromtreatmentrelatedchangeinmalignantbraintumorsthequesttobeatthetoughestcases
AT greenmarka hybrid18ffluoroethyltyrosinepetandmriwithperfusiontodistinguishdiseaseprogressionfromtreatmentrelatedchangeinmalignantbraintumorsthequesttobeatthetoughestcases
AT hutchinsgaryd hybrid18ffluoroethyltyrosinepetandmriwithperfusiontodistinguishdiseaseprogressionfromtreatmentrelatedchangeinmalignantbraintumorsthequesttobeatthetoughestcases
AT veronesimichaelc hybrid18ffluoroethyltyrosinepetandmriwithperfusiontodistinguishdiseaseprogressionfromtreatmentrelatedchangeinmalignantbraintumorsthequesttobeatthetoughestcases